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Antiepileptic drugsAbstract Background: Epilepsy often requires long-term antiepileptic drug therapy. Antiepileptic
drugs are potentially an effective treatment for patients with epilepsy. Poor adherence is, however,
very common in patients experiencing side-effects due to AEDs.
The aim of this study: The aim of this study was to evaluate the effects of AED monotherapy by
VPA on alterations in serum calcium levels and statural growth and body mass index in pediatric
patients newly diagnosed with epilepsy.
Patients and methods: The present study included 25 children, newly diagnosed with epilepsy and
maintained on VPA monotherapy for at least one year. The serum levels of patients taking VPA
were routinely monitored. Another 25 children with a history of simple febrile convulsions were
included as a control group. All patients and controls were selected from Al-Azhar University hos-
pital (new Damietta) during the period from June 2011 to June 2012. The main screening assess-
ments included seizure frequency, vital signs, physical and neurologic examinations, medical
history, and standard clinical laboratory tests (e.g., CBC, BUN, SGPT, SGOT); all these parame-
ters were estimated at the start of the study, at 6 and 12 months. Weight and height measurements
were recorded at the start of the study and at 6 and 12 months of continuous treatment of valproic
acid. In addition serum calcium and glucose levels were obtained at the same time.
Results: There was no significant difference between study and control groups at basal time regard-
ing height, weight or BMI. On the other hand, there was a significant increase of weight and BMI
and a decrease of height centiles at 6 months and 1 year; and as regards serum glucose, there was no
significant difference between study and control group at basal time, while there was a significant
increase in the study group in the control group at 6 months and 1 year. On the other hand, there
was no significant difference between cases and controls as regards serum calcium at any time.
70 H.M.A. Maksoud et al.Conclusion: Childhood and adolescence are crucial periods in which to attain peak bone mass, and
it is a crucial period for growth in general; and most patients with epilepsy are diagnosed and trea-
ted in this period, therefore, AEDs, and especially VPA, should be used with caution in pediatric
patients with epilepsy.
 2016 The Egyptian Pediatric Association. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
According to WHO, epilepsy is one of the most common neu-
rological disorders affecting approximately 50 million peo-
ple.32 Epilepsy can be defined as a chronic condition
characterized by recurrent clinical events or epileptic seizures,
which occur in the absence of a metabolic or toxic disease or
fever.8 Epilepsy often requires long-term antiepileptic drug
(AED) therapy. Antiepileptic drugs (AEDs) are potentially
an effective treatment for patients with epilepsy. Treatment
failure and poor adherence are, however, very common in
patients experiencing side-effects due to AEDs. In approxi-
mately 25% of the patients, side-effects lead to treatment dis-
continuation.21,27 Valproic acid is effective in treatment of all
types of epilepsy. It is among the most widely used antiepilep-
tic drugs in clinical practice.6
In human long bones, the growth plate is made up of chon-
drocytes at different stages of differentiation, and is divided
histologically into three distinct zones: resting, proliferative,
and hypertrophic.28 Longitudinal bone growth is achieved
through the action of chondrocytes in the proliferative and
proliferative zones of the growth plate.23 Bone provided sys-
temic and local hormones, calcium and other chemicals, to
maintain the intra-and extracellular mineral pools and can
work with osteoblasts, osteocytes, and extracellular matrix
proteins to mineralize osteoid.22 Calcium is an important ele-
ment for normal epiphyseal growth plate development, and
changes in extracellular calcium affect the function of chon-
drocytes.24 Proliferation of epiphyseal growth plates results
from complex interactions between hormones and growth fac-
tors, which may directly or indirectly affect the serum levels of
calcium and the condition of those cells, leading to final
stature.
Although some studies suggest that patients with epilepsy
treated with AEDs have an increased risk of fractures, low
bone mineral density (BMD), and abnormalities in bone meta-
bolism, skeletal diseases associated with long-term AED treat-
ment are seriously unrecognized.19,26
Evidence suggests that patients with epilepsy are predis-
posed to bone problems and fractures. However, one meta-
analysis concluded that the deficit in bone mineral density
was too small to explain the increase in the risk of fractures
in patients with epilepsy.31 Bone abnormalities such as short
stature, abnormal dentition, rickets, and osteomalacia have
been reported to be linked to the use of AEDs.10
Weight gain is a well-known adverse effect of VPA treat-
ment, occurring in 40% of children.4 Weight gain is the most
common reason for patients to discontinue VPA treatment.30
In one study, 38% of VPA-treated patients gained more
than 10% of their body weight compared with 8% of patients
treated with lamotrigine.3 Further, weight gain associated with
VPA seems to be appetite-related and not metabolic.7Aim of the work
The aim of this study was to evaluate the effects of AED
monotherapy by VPA on alterations in serum calcium levels
and statural growth and body mass index in pediatric patients
newly diagnosed with epilepsy.
Patients and methods
The present study included 25 children, newly diagnosed with
epilepsy and maintained on VPA monotherapy for at least one
year (starting dose 20 mg/kg/day, maintenance dose 20–40 mg/
kg). The serum levels of patients taking VPA were routinely
monitored, and the levels kept within the therapeutic range
(50–100 lg/mL). Another 25 children with a history of simple
febrile convulsions were included as a control group. All
patients and controls were selected from Al-Azhar University
hospital during the period from June 2011 till June 2012 from
Pediatrics, Neurology and Emergency departments. An
informed consent was obtained from the guardian to partici-
pate in the study and the study protocol was approved by
the local ethics committee. Epileptic children were classified
according to the International League Against Epilepsy
(ILAE) Commission on Classification and Terminology
2005,1 into generalized and focal epilepsy.
Inclusion criteria
(1) Epilepsy patients using Valproic Acid Monotherapy for
at least 1 year.
(2) Age 2–14 years.
(3) Either sex.
Exclusion criteria
(1) A history of taking medications that affect bone meta-
bolism (e.g., steroids, diuretics, vitamin D, calcium sup-
plements, bisphosphonates, or calcitonin);
(2) Any endocrine or medical disorders (e.g., hypothy-
roidism or renal diseases);
(3) A history of nutritional deficiency;
(4) Limitations in ambulation or daily physical activity;
(5) Any progressive neurological disorders other than epi-
lepsy; and
(6) Clinical/biochemical evidence of rickets or growth
retardation.
The main screening assessments included seizure frequency,
vital signs, physical and neurologic examinations, medical his-
tory, and standard clinical laboratory tests (e.g., CBC, BUN,
Effect of valproic acid on child growth 71SGPT, SGOT); all these parameters were estimated at the start
of the study, at 6 and 12 months. Weight and height were mea-
sured with standard techniques, as described elsewhere,17 using
a scale accurate to 0.1 kg and a stadiometer accurate to 0.1 cm;
body mass index (BMI) was calculated by dividing weight in
kilograms by squared height in meters. Weight, height, and
BMI values were compared with CDC reference standards to
obtain centiles.16 Weight and height measurements were
recorded at the start of the study and at 6 and 12 months of
continuous treatment of valproic acid. A blood sample was
obtained between 8:30 and 9:00 am after an overnight fast
and before breakfast. The following parameters were measured
using commercially available radioimmunoassay kits: serum
total and ionized calcium, serum glucose and serum VPA con-
centration. Cobas c501 (Roche Diagnostics, Mannheim, Ger-
many) and NOVA CCX (NovaBiomedical, Waltman, MA,
USA) were used for the measurement of serum total calcium
levels, respectively. Serum levels of valproic acid were deter-
mined using Abbott TDx analyzer (Abbott laboratories) as
described by Newman et al.18
Statistical analysis
All statistical analyses were performed using SPSS software,
version 16.0 (Chicago, IL, USA). Quantitative data were
expressed as mean ± standard deviation (SD). Comparisons
of data were conducted with Student’s t test and used to com-
pare between two means, and qualitative data were presented
as relative frequency and percent distribution and for compar-
ison between groups Chi square test was used. A p value <0.05
was considered statistically significant.
Results
As regards characteristics of studied cases, it was presented in
Table 1: there was no significant difference between cases and
controls as regards age, sex, hemoglobin, liver enzymes or
BUN. Epilepsy was general in 32% of cases and focal in
68% of cases; and serum valproic acid was in the normal level
(mean ± SD 63.76 ± 6.50).
As regards anthropometric measurement centiles; there was
no significant difference between study and control groups at
basal time regarding height, weight or BMI. On the other hand,
there was a significant increase of weight and BMI and a
decrease of height centiles at 6 months and 1 year (Table 2).
Regarding serum glucose, there was no significant differ-
ence between study and control group at basal time, whileTable 1 Characteristics of studied groups.
Study
Age (years) 7.80 ± 2.32; 5–13
Sex (male) 16(64.0%)
Epilepsy type
General 8(32.0%)
Focal 17(68.0%)
Serum levels of valproic acid 63.76 ± 6.50; 54–75
Hemoglobin 10.59 ± 0.78; 9.40–12
ALT 23.16 ± 3.94; 13–30
AST 23.08 ± 3.20; 16–30
BUN 24.80 ± 3.06;20–31there was a significant increase in the study group when com-
pared to the control group at 6 months and 1 year. On the
other hand, there was no significant difference between cases
and controls as regards serum calcium at any time. Finally,
there was a significant increase of ALT in the study group
when compared to the control group at 6 months and 1 year.
This difference was not found for AST (Table 3).Discussion
Valproic acid (VPA) is a broad-spectrum anticonvulsant. It is
not a sedative and is associated with fewer cognitive or behav-
ioral effects than other drugs such as Phenobarbital.33 On the
other hand, VPA causes numerous side effects that can inter-
fere with treatment compliance and weight gain.15
The present study was designed to evaluate the effects of
VPA on alterations in serum calcium levels and statural
growth, body mass index in pediatric patients newly diagnosed
with epilepsy. Results of the study revealed that, there was a
significant decrease of linear growth (height) and increase of
weight and BMI with advancement of time on regular VPA
monotherapy; and although, it was in normal levels, there
was a significant increase of serum glucose levels at 6 and
12 months, while serum calcium showed no changes. In sup-
port of our findings, Sheth et al.25 and Kafali et al.14 reported
decreased bone mass in the lumbar spine and middle of the dis-
tal radius in children without physical handicaps who were
treated with VPA for P6 or 18 months. This suggests that
VPA can disturb bone growth.
In the present study, no significant difference was seen
between study and control groups as regards total calcium
levels. These results and others support the notion that AEDs
can cause bone loss without inducing hypocalcemia and vita-
min D deficiency, suggesting that other mechanisms may be
responsible. In addition, it was reported that, the reported
effects of VPA on bone loss in patients with epilepsy are
diverse, including accelerated or no bone loss,13,29 hyper- and
hypocalcemia,20 or normal serum calcium level.5
Results of the present study are in agreement with Beydoun
et al.,2 who reported that, some patients develop a substantial
weight gain on VPA, which can be treatment limiting. Differ-
ent mechanisms had been proposed to explain weight gain with
VPA therapy. One of these is an increased consumption of
food and energy-rich beverages because of an increased appe-
tite and abnormal thirst has been suggested. In addition, the
study by Verrotti et al.29 revealed that abnormal glucose home-
ostasis was identified in 45% of patients.Control Test P value
7.60 ± 1.35; 5–10 0.37 0.71(NS)
18(72%) 0.36 0.54(ns)
10.62 ± 0.73; 9.80–12.30 0.15 0.88(NS)
22.08 ± 4.08; 12–29 0.95 0.34(NS)
23.72 ± 2.62; 19–30 0.77 0.44(NS)
23.52 ± 3.46;19–33 1.38 0.17(NS)
Table 2 Comparison between study and control groups as regards anthropometrics for age centiles.
Study Control t P value
Height for age centile Basal 39.60 ± 14.20 42.20 ± 9.90 0.75 0.45 (NS)
At 6 months 32.20 ± 12.25 48.0 ± 9.12 5.16 <0.001*
At 1 year 34.80 ± 18.79 53.60 ± 12.70 4.14 <0.001*
Weight for age centile Basal 41.40 ± 18.62 45.40 ± 14.06 0.85 0.38(NS)
At 6 months 67.80 ± 16.71 51.20 ± 12.93 3.92 <0.001*
At 1 year 80.20 ± 14.02 55.40 ± 13.68 6.32 <0.001*
BMI for age centile Basal 48.60 ± 23.91 47.80 ± 24.11 0.12 0.91(NS)
At 6 months 83.44 ± 13.14 56.48 ± 19.27 5.77 <0.001*
At 1 year 89.48 ± 8.67 63.20 ± 18.58 6.40 <0.001*
* Significant.
Table 3 Comparison between study and control groups as regards serum glucose and total calcium.
Study Control t P value
Serum glucose Basal 90.52 ± 6.80 88.32 ± 7.53 1.08 0.28(NS)
At 6 months 97.44 ± 6.04 89.32 ± 4.67 5.31 <0.001*
At 1 year 96.08 ± 6.15 91.68 ± 2.65 3.28 0.002*
Serum calcium Basal 9.04 ± 0.34 9.18 ± 0.47 1.23 0.22(NS)
At 6 months 8.88 ± 0.40 8.91 ± 0.44 0.23 0.81(NS)
At 1 year 8.86 ± 0.37 8.93 ± 0.30 0.70 0.48(NS)
ALT Basal 23.16 ± 3.94 22.08 ± 4.08 0.95 0.34(NS)
At 6 months 32.28 ± 4.28 22.40 ± 4.26 8.17 <0.001*
At 1 year 38.76 ± 4.41 23.48 ± 5.25 11.13 <0.001*
AST Basal 23.08 ± 3.20 23.72 ± 2.62 0.77 0.44(NS)
At 6 months 24.48 ± 2.53 25.16 ± 2.74 0.75 0.45(NS)
At 1 year 25.28 ± 3.34 25.72 ± 2.90 0.49 0.62(NS)
* Significant.
72 H.M.A. Maksoud et al.On the other hand, Isojarvi et al.11 reported that, in patients
with marked weight gain, increased insulin concentrations and
insulin/glucose ratios were observed. Higher insulin and insu-
lin/glucose levels may be involved in weight gain by stimulat-
ing appetite. On the other hand, in the patients without
weight gain, who showed no increased appetite, no increase
in serum insulin or insulin/glucose levels was demonstrated.
These findings suggest that an increase in serum insulin and
insulin/glucose levels may cause weight gain, possibly by stim-
ulating appetite. The findings of decreased insulin levels within
2 months and body weight within 12 months suggest that
hyperinsulinemia may play a primary role in VPA-induced
metabolic changes.
Finally, elevated liver enzyme (ALT) at 6 months and
1 year after starting treatment reflected the toxic effect of val-
proic acid on the liver. These results are in accordance with
Gopaul et al.9 who reported that, hepatitis was more fre-
quently observed in patients taking valproic acid. This effect
was reported to be caused by free radicals.12Conclusion
Childhood and adolescence are crucial periods in which to
attain peak bone mass, and it is a crucial period for growth
in general; and most patients with epilepsy are diagnosed
and treated in this period, therefore, AEDs, and especiallyVPA, should be used with caution in pediatric patients with
epilepsy.
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